
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Recent discussions among investors of Oxford Biomedica Plc (OXB) highlight a mix of cautious optimism and frustration, influenced by broader market conditions and specific company developments. Notably, sentiment seems subdued as investors express concern about the company's upcoming results in early April, with many reflecting on their trading strategies amidst fluctuating share prices. Some investors like "steeplejack" have sold a significant portion of their holdings due to market nervousness, while "brucie5" has noted a historical support level around £3, which investors hope will hold. "harry s truman" remarked that significant changes in stock value could emerge depending on announcements from the company, exemplifying the uncertainty that looms over OXB.
Financial highlights shared in the discussions include a recognition of a one-time expense of $5.4 million linked to a partnership with Bristol Myers Squibb (BMS), which is set to affect the company's financial guidance. This expense, along with ongoing developments in their gene therapy products and the strategic importance of becoming a preferred manufacturer for BMS, underscores potential long-term growth prospects despite immediate pressures. Investor comments reflect a desire for clearer communication from OXB regarding their operations, as observed by comments related to the company's communication practices. Amid this uncertainty, one investor astutely noted, "Resilience is required to solve the puzzle," indicating the sentiment that patience may be crucial while navigating potential short-term volatility.
Overall, while investors remain hopeful about OXB's strategic advancements, their discussions reveal that the community is grappling with a lack of timely communication and clarity on future developments, contributing to a cautious approach in trading the stock.
Show more
Oxford Biomedica PLC (LSE: OXB) announced the total voting rights associated with its ordinary shares as of February 28, 2025. The company reported that its issued share capital consists of 105,975,816 ordinary shares, all of which hold a nominal value of 50 pence each. Notably, there are no shares held in treasury, providing clarity to shareholders regarding their voting rights. This total can be utilized by investors to ascertain their interest in OXB under the Financial Conduct Authority's (FCA) Disclosure Guidance and Transparency Rules.
In the broader context of its operations, OXB continues to position itself as a leader in cell and gene therapy manufacturing services. The company focuses on quality and innovation as key drivers in its sector, which is increasingly vital due to the growing demand for advanced therapeutic modalities. Such announcements reflect Oxford Biomedica's commitment to transparency and engagement with its shareholder base while reinforcing its robust standing in the biotechnology industry.
Show more
Hi Harry, Doesn’t that RNS suggest that black rock has increased their holding from below 5 to 5.03%, looking at the A+ B column? They just moved more into CFD’s. |
I realise I'm on thin ice here given my interpretation of yesterday, but... |
Sometimes buses crash. |
Talk about buses... |
BR currently hold a 45% stake in M&G, through their various tributaries. |
Presuming that M&G have been selling over a period then you would have expected disclosure as their shareholding fell through the bands ie 9 percent ,8 percent etc but that hasn't occurred.So maybe it was a block trade.Yet given that M&G no longer think they have a notifiable interest at just under 5%,they appear to be conforming with the disclosure rules pertaining to a non UK issuer.Helpful but invariably confusing these disclosures.i suppose you just have to make do with the fact that we know M & G have sold half their holding. |
An understandable mistake Harry if indeed it is a mistake.I suppose M&G know better than us.I thought it was 3 per cent.Disclosure must be reported within a couple of trading days unless its a non UK issuer,then its 4 days.Sets of rules cloaked in exemptions and complications that have companies wishing to go private.Under DTR 5.1.2R, a person must notify the issuer of the percentage of its voting rights they hold as a shareholder or are deemed to hold through their direct or indirect holding of financial instruments falling within DTR 5.3.1R (1) or a combination of such holdings, if the percentage of those voting rights:reaches, exceeds or falls below 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% and each 1% threshold thereafter up to 100% (or in the case of a non-UK issuer on the basis of thresholds at 5%, 10%, 15%, 20%, 25%, 30%, 50% and 75%) as a result of an acquisition or disposal of shares or financial instruments falling within DTR 5.3.1 R; orreaches, exceeds or falls below an applicable threshold in (1) as a result of events changing the breakdown of voting rights and on the basis of information disclosed by the issuer in accordance with DTR 5.6.1 R and DTR 5.6.1A R. |
Thanks bunlop. I honestly thought it was simply UK 3% non-UK 5% but have edited now to make me look slightly less daft. |
Harry. I think funds have a 5% notification threshold. |
M&G have held the position in OXB for many years, at varying levels. |
My mistake there - days and years - confusing people since... |
They bought the entire position between June 23 and June 24 according to the accounts so they may have made a decent turn and decided to move on. Perhaps their best performer in the fund looking at some of the other holdings - said in jest of course.... |
Hopefully they were placed with one party at a discount to the recent dip, and a further announcement by that party of an increased holding will give us all a bit of a boost............bef |
M&G holds OXB at 2% in M&G recovery fund....is that where it is being sold down from? |
M&G were at 7% in the annual report. That was before the last tranche of the IM shares were issued, so the effective holding would be closer to 6.7%. So the sell down has been less severe than the holdings announcement implies. |
Seeing as that represents over 5 million shares (a little over half their holding), the sale has either been worked over a significant period of time or else, if a large block sale, we should soon expect to see an announcement of the counter-party who bought them. |
#9568. .... And so it does! |
M&G the British Sports car manufacturer selling. |
You wonder if it’s been a tree shake before news? |
I don't know Dom, but today ADVFN popup ads for me have been for Castle Air private VIP helicopter charters. I'm taking it as a sign. |
Looking like we'll close back over £4. What on earth is going on? |
Appreciate that, thank you. So basically the advice would always be to ring up in person to get the best price for a sizable quantity or I suppose simply set a limit trade and hope for the best. I'd always assumed that the partial order book which we can see on OXB's website is the limit trades sat there waiting to either be taken or expire, but had no way to know that for sure. |
Below is a commentary on NMS .I would guess that normal market size for OXB is perhaps as low as a thousand shares.This means that invariably,a marketmaker will find himself working an order.In the past,a market maker would offer to do an initial trade which was bigger than NMS to kick off the order presuming he was given the balance of the order to work on.Such niceties may of long gone but its not in the interests of a reasonable size holder to go dumping stock in a disorganised fashion and compromise his portfolio valuation.In a thin market like OXB, MMs will be keen to keep a low profile.Its difficult to know what they're up to.Most believe that when an MM pushes up the bid price,he's working a buy order but its quite feasible that he's carrying stock and is trying to offload it by encouraging buyers on the blue. "if you call your broker and ask them to deal in the stock, you can be guaranteed a minimum fill in a certain size and price at least. But if you request a quoted price to buy or sell online then the market makers are not obliged to honour any price or size of transactions. This means that no minimum price or size can be guaranteed when you request a market maker quote through your online broker." |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 301.00 |
Offer Price | 302.00 |
Open | 297.00 |
Shares Traded | 217,322 |
Last Trade | 16:35:28 |
Low - High | 295.00 - 304.00 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7380 |
PE Ratio | -1.73 |
Market Cap | 314.71M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions